Expertise in
3
conditions

Tom M. Hillary

Leuven, VLG, BE 
Expertise in
3
conditions
Leuven, VLG, BE 

Overview

Tom Hillary practices practicing medicine in Leuven, Belgium.

Mr. Hillary is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Psoriasis, Severe Acute Respiratory Syndrome (SARS), COVID-19, and Plaque Psoriasis.

He is actively involved in clinical research, co-authoring 34 peer reviewed articles and participating in 1 clinical trial.

Gender

Male

Locations

Leuven, VLG, Belgium
Other Locations
Brussels, BRU, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Baricitinib in Combination With Topical Corticosteroids in Adult Patients With Moderate-to-Severe Atopic Dermatitis Who Have Experienced Failure to Cyclosporine or Are Intolerant to, or Have Contraindication to, Cyclosporine
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Baricitinib in Combination With Topical Corticosteroids in Adult Patients With Moderate-to-Severe Atopic Dermatitis Who Have Experienced Failure to Cyclosporine or Are Intolerant to, or Have Contraindication to, Cyclosporine
Enrollment Status: Completed
Publish Date: May 14, 2024
Intervention Type: Drug
Study Drugs: Baricitinib, Corticosteroid
Study Phase: Phase 3

34 Total Publications

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (BeNeBio study): An International, Pragmatic, Multicentre, Randomised, Controlled, Non-Inferiority Trial.
Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (BeNeBio study): An International, Pragmatic, Multicentre, Randomised, Controlled, Non-Inferiority Trial.
Journal: The Lancet regional health. Europe
Published: January 29, 2026

Frequently Asked Questions about Tom M. Hillary

Is Tom M. Hillary a top-rated expert for Psoriasis?

MediFind is an objective health platform that identifies experts based on real-world data. Tom M. Hillary is classified as an Advanced expert for Psoriasis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Tom M. Hillary participate in research or clinical trials?

Yes. Tom M. Hillary has published 34 articles and abstracts on conditions like Psoriasis. You can view a list of Tom M. Hillary's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hillary's expertise for a condition
ConditionClose
      View All 14 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile